Epizyme, Inc.
EPZMDelisted Aug 12, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001571498
Epizyme, Inc. was delisted on Aug 12, 2022; its insiders filed their last Form 4 on Aug 16, 2022; 94 institutions reported holding it in 13F filings for Q2 2022, worth $187.0M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:33 PM ET
Revenue flow, FY2021
Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2021: $251.1M (671.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 10, 2022 | Feb 23, 2021 | Jan 6, 2020 | Feb 26, 2019 | – |
| Revenue | $37.4M | $15.8M | $23.8M | $21.7M | – |
| Cost of revenue | $10.5M | $5.07M | – | – | – |
| Research and development | $131.0M | $110.9M | $132.6M | $105.8M | $109.7M |
| Selling, general and administrative | $134.0M | $125.2M | $68.3M | $44.0M | $37.2M |
| Operating income | -$238.0M | -$225.4M | -$177.1M | -$128.1M | -$136.8M |
| Income tax | $22.0K | $114.0K | $58.0K | $57.0K | -$336.0K |
| Net income | -$251.1M | -$231.7M | -$170.3M | -$123.6M | -$134.3M |
| EPS, basic | $-2.45 | $-2.29 | $-1.93 | $-1.72 | $-2.18 |
| EPS, diluted | $-2.45 | $-2.29 | $-1.93 | $-1.72 | $-2.18 |
| Weighted shares, basic | 102.6M | 101.0M | 89.9M | 71.9M | 61.5M |
| Weighted shares, diluted | 102.6M | 101.0M | 89.9M | 71.9M | 61.5M |
| Margins and growth | |||||
| Operating margin | -635.9% | -1430.1% | -744.3% | -590.3% | – |
| Net margin | -671.0% | -1470.0% | -715.5% | -569.7% | – |
| Revenue growth, year over year | +137.5% | −33.8% | +9.7% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 10, 2022 | Feb 23, 2021 | Jan 6, 2020 | Feb 26, 2019 | – |
| Cash and equivalents | $98.3M | $168.2M | $139.5M | $86.7M | $226.7M |
| Short-term investments | $78.5M | $205.4M | $241.6M | $153.6M | $49.8M |
| Accounts receivable | $6.57M | $3.10M | $2.57M | $20.1M | $382.0K |
| Total current assets | $206.0M | $405.1M | $399.2M | $272.5M | $285.8M |
| Property, plant and equipment | $1.54M | $2.15M | $2.22M | $2.06M | $2.53M |
| Intangible assets | $42.8M | $47.0M | – | – | – |
| Total assets | $289.0M | $473.6M | $424.6M | $275.5M | $289.4M |
| Accounts payable | $10.3M | $10.2M | $8.78M | $4.78M | $7.00M |
| Short-term debt | $0 | $0 | $0 | – | – |
| Total current liabilities | $45.2M | $43.4M | $34.4M | $37.8M | $24.7M |
| Long-term debt | $216.5M | $215.7M | $23.3M | – | – |
| Shareholders' equity | -$20.7M | $184.9M | $331.1M | $233.0M | $235.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 10, 2022 | Feb 23, 2021 | Jan 6, 2020 | Feb 26, 2019 | – |
| Operating cash flow | -$226.9M | -$206.3M | -$147.2M | -$121.6M | – |
| Capital expenditures | $486.0K | $880.0K | $594.0K | $299.0K | $984.0K |
| Free cash flow | -$227.3M | -$207.2M | -$147.8M | -$121.9M | – |
| Depreciation and amortization | $5.25M | $3.98M | $840.0K | $1.05M | $1.64M |
| Stock-based compensation | $26.8M | $27.6M | $18.0M | $12.0M | $11.4M |
| Investing cash flow | $125.5M | -$14.6M | -$85.3M | -$102.6M | – |
| Financing cash flow | $31.5M | $249.7M | $286.3M | $84.2M | – |
| Net change in cash | – | – | – | – | $148.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 71.6% | 175.2% | 75.7% | 55.3% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 5, 2022 | 168.4M | +64.7% | SEC |
| May 4, 2022 | 164.9M | +61.7% | SEC |
| Feb 24, 2022 | 164.5M | +61.6% | SEC |
| Nov 4, 2021 | 103.9M | +2.3% | SEC |
| Aug 4, 2021 | 102.2M | +0.8% | SEC |
| Apr 30, 2021 | 102.0M | +0.9% | SEC |
| Feb 18, 2021 | 101.8M | +1.0% | SEC |
| Oct 30, 2020 | 101.6M | +11.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.